Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)

BACKGROUND: The World Health Organization recommends intravenous amikacin for the treatment of MDR-TB at a dose of 15 mg/kg. However, higher doses are associated with significant toxicity. METHODS: Patients with MDR-TB treated at our institution receive amikacin at 8–10 mg/kg, with dose adjustment b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabur, Natasha F., Brar, Mantaj S., Wu, Lisa, Brode, Sarah K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945371/
https://www.ncbi.nlm.nih.gov/pubmed/33691624
http://dx.doi.org/10.1186/s12879-021-05947-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945371/
https://www.ncbi.nlm.nih.gov/pubmed/33691624
http://dx.doi.org/10.1186/s12879-021-05947-6

Ejemplares similares